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ABSTRACT: We have previously reported asymmetric syn-
theses and absolute configuration assignments of the aglains
(+)-ponapensin and (+)-elliptifoline and proposed a biosyn-
thetic kinetic resolution process to produce enantiomeric
rocaglamides and aglains. Herein, we report a biomimetic
approach for the synthesis of enantiomerically enriched aglains
and rocaglamides via kinetic resolution of a bridged ketone
utilizing enantioselective transfer hydrogenation. The method-
ology has been employed to synthesize and confirm the absolute
stereochemistries of the pyrimidone rocaglamides (+)-aglaiasta-
tin and (−)-aglaroxin C. Additionally, the enantiomers and racemate of each metabolite were assayed for inhibition of the heat-
shock response, cytotoxicity, and translation inhibition.
■ INTRODUCTION
Plants of the genus Aglaia are known to produce a variety of
unique secondary metabolites including the cyclopenta[b]-
benzofurans methyl rocaglate (1),1 aglaiastatin (2),2 and
aglaroxin C (3)2b,3 and the cyclopenta[b,c]benzopyran (aglain)
ponapensin (4)4 (Figure 1). These metabolites and derived
synthetic analogues thereof have been reported to have potent
antitumor,2−5 anti-inflammatory,6 neuroprotective,7 cardiopro-
tective,8 and serine hydrolase inhibitory activities.9 The natural
product families are proposed10 to arise from a common aglain
intermediate. From previous work in our laboratory assigning
the absolute stereochemistry of (−)-ponapensin (4),11a it was
determined that rocaglates/rocaglamides and the aglains
(−)-ponapensin (4) and (−)-elliptifoline11 arise from inter-
mediates with opposite absolute configuration.
In previous studies, we proposed11a that ketoreductase or
reductoisomerase enzymes12 could differentiate between the
enantiomers of ketone 5a, selecting for either direct reduction
or rearrangement followed by reduction as part of a parallel
kinetic resolution13 process (Figure 2). In the case of kinetic
resolution of aglain ketone 5a, both enantiomers may be
converted to bioactive natural products which led us to
investigate the application of a reductive, chemical kinetic
resolution approach to enantiopure ketone 5a.
Noyori and co-workers have previously used chiral
ruthenium complexes in the kinetic resolution of racemic
secondary alcohols.14 Metz and co-workers15 recently demon-
strated the utility of this approach for the reductive, kinetic
resolution of racemic flavanone substrates. Herein, we report
the kinetic resolution of aglains such as 5a via reduction of a
chiral, racemic bridged ketone and its application toward the
total syntheses of the pyrimidones (+)-aglaiastatin (2) and
(−)-aglaroxin C (3).
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Figure 1. Aglain and rocaglate natural products. Absolute stereo-
chemistries are shown for 1 and 4; relative stereochemistries are
depicted for 2 and 3.
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■ RESULTS AND DISCUSSION
Biomimetic Kinetic Resolution. Our initial investigations
utilized conditions recently reported by Metz and co-workers15
for asymmetric transfer hydrogenation of racemic flavanones via
Rh (III) catalysis employing hydrate 5b11a which to our delight
afforded (−)-6 in 95% ee after 40% conversion (Table 1, entry
1). The absolute stereochemistry was determined through
comparison to (+)-6, previously assigned through X-ray crystal
structure analysis and synthesis of (−)-methyl rocaglate from a
common intermediate.11a Even after a more than 5-fold
increase in reaction time (entry 2), we could not push the
reaction to 50% conversion. After further optimization, CH2Cl2
was found to be the solvent of choice, providing optimal
conversion (entry 5). Low conversions observed (entries 1, 2,
and 4) were likely due to the insolubility of hydrate 5b in both
ethyl acetate and THF. In situ dehydration of 5b with 4 Å
molecular sieves (entry 3) led to no reaction, suggesting that
the molecular sieves were interfering with the process.
Furthermore, subjection of ketone 5a to the reaction conditions
did not produce significantly different results from use of
hydrate 5b. Other metal hydride and ligand systems were tested
(entries 6−8), each affording lower enantioselectivity or in one
case no reactivity (entry 8).
What was perhaps more intriguing than the excellent
enantioselectivity was the complete diastereoselectivity ob-
served. Based on our previous reductions of ketone 5a and
hydrate 5b,11a we hypothesized that non-coordinating reducing
agents would preferably attack the in situ generated ketone
away from the phloroglucinol ring. Since the rhodium catalyst
system is sterically encumbered, we believe that other modes of
stabilization enhance attack from the phloroglucinol face. In the
aforementioned example of kinetic resolution of flavanones
through catalytic asymmetric transfer hydrogenation, Metz and
co-workers15 proposed an assembly for kinetic resolution of
flavanones featuring stabilizing CH−π interactions16 between
the methyl groups on the Cp* ligand and the aromatic
substituent of the ketone. Figure 3 depicts models generated
using Spartan ‘1017 for both favored and disfavored
enantiomers of aglain ketone substrates. In the case of the
favored substrate/catalyst assembly (Figure 3A) we propose
that, in addition to the stabilizing CH−π interaction, a
hydrogen bond between the tertiary alcohol of substrate
(−)-5a and the sulfonyl oxygen of the catalyst helps to direct
the chiral reducing agent. In the case of the disfavored
substrate/catalyst (Figure 3B), this hydrogen bond interaction
is not evident which allows (−)-5a to be selectively reduced
through assembly A. This is in contrast to the assembly
proposed by Metz and co-workers in which a destabilizing
steric interaction led to selective reduction of one enantiomer.15
To evaluate the scope of the kinetic resolution on different
substrates, we synthesized a variety of aglain ketone analogs and
subjected them to the optimized conditions (Table 2). Our aim
was to manipulate the electronics of the aromatic system and
Figure 2. Proposed biosynthetic kinetic/parallel kinetic resolution to
access both natural product families.
Table 1. Metal and Ligand Screen for Catalytic, Asymmetric
Reduction
entry catalyst solvent time, h conv (ee), %
1 A EtOAc 3 40 (95)
2 A EtOAc 16 40 (96)
3 A EtOAca 6 trace
4 A THF 3.5 43 (95)
5 A CH2Cl2 5 50 (96)
6 B CH2Cl2 5 63 (69)
7 C CH2Cl2 5 60 (43)
8 D CH2Cl2 5 nr
a4 Å molecular sieves used.
Figure 3. Proposed models for the favored (A) and disfavored (B)
diastereomeric assemblies.
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observe its effect on the kinetic resolution. Desmethoxy
substrate 7 produced both a lower conversion and decreased
enantioselectivity (entry 2). When the aryl ring was not directly
adjacent to the reactive ketone, the reaction did not occur as
demonstrated by attempted reduction of β-keto ester 8 (Table
2, entry 3). Results using the 4′-Br-substituted derivative 918 are
identical to that of the trimethoxy system suggesting that the
substitution of the aryl group coplanar to the ketone has little
effect. Difluorinated substrate 1019 led to an erosion of ee more
so than the desmethoxy system. This is likely due to the less
electron rich π system being unable to form a strong CH−π
bond with the Cp* ligand20 thus slowing conversion. To
evaluate the ee of the starting materials, the reisolated material
was converted to methyl rocaglate analogs 14 and 15.
Enantioenriched (+)-7 was directly reduced to (+)-11 using
NaBH(OAc)3.
11a
Total Syntheses of (+)-Aglaiastatin and (−)-Aglaroxin
C. To demonstrate the utility of the kinetic resolution
methodology, we targeted asymmetric syntheses of the
pyrimidone rocaglamide natural products (+)-aglaiastatin (2)
and (−)-aglaroxin C (3). The absolute configuration of
(+)-aglaiastatin (2) has been proposed to be identical to
other members of the rocaglate family and circular dichroism
spectra supports this notion.21 We intended to use our method
to conclusively determine the absolute stereochemistry of 2 and
to compare it to that of both (−)-ponapensin (4) and
(−)-methyl rocaglate (1). The synthesis of aglaiastatin (2,
Scheme 1) involved base-mediated ketol rearrangement of
aglain (+)-5b to a keto-rocaglate intermediate followed by ester
amide exchange to afford butyramide dimethyl acetal 16 similar
to an intermediate employed by Watanabe and co-workers.22
Under acidic hydrolysis conditions, acetal 16 formed the
hemiaminal derivative 17 (cf. Scheme 2) which was heated with
ammonium acetate to form (+)-aglaiastatin (2) ([α]27D =
+86.1° synthetic (c 0.7, CHCl3), [α]
20
D = +45.7° natural (c
0.19, CHCl3)
2b) in 55% yield (10:1 dr, 4 steps). (−)-Aglaroxin
C (3) (([α]27D = −49.2° synthetic (c 0.1, CHCl3), [α]20D =
−50.1° natural (c 0.41, CHCl3)
2b) was obtained in 66% yield
via dehydrogenation of (+)-aglaiastatin (2) with DDQ.
Interestingly, treatment of epi-aglaiastatin 18 (cf. Scheme 2)
with DDQ also provided aglaroxin C (3).
With (+)-aglaiastatin (2) obtained in a 10:1 ratio to its C5a‴
epimer 18 (epi-aglaiastatin), we conducted a number of
experiments to explain the high diastereoselectivity of the
putative N-acyliminium cyclization. When hemiaminal 17 was
heated at 60 °C for 2 h in the presence of ammonium acetate,
we observed a 10:10:1 ratio of (±)-aglaiastatin (2):oxazinone23
(±)-19: C5a‴ epimer (±)-18 (Scheme 2) in 55% yield.
Furthermore, we found that (±)-19 could be synthesized
directly by heating (±)-17 overnight in the presence of
magnesium sulfate (42%).19 The structure of 19 and its
configuration at C5a‴ was determined via X-ray crystal
structure analysis (Figure 4).19 When hemiaminal (±)-17 was
treated with formic acid and ammonium formate at room
temperature,22 we observed a 1.2:1.2:1 ratio of (±)-2:(±)-19:
(±)-18 in 69% yield (Scheme 2). The product ratio seems to
be controlled by the nature of the N-acyliminium counterion, as
thermolysis of (±)-17 in the presence of ammonium formate
led to the same distribution of products (Scheme 2). Epimer
(±)-18 could not be converted to (±)-aglaiastatin (2) when
subjected to ammonium acetate/heat or ammonium formate/
formic acid. Likewise, (±)-aglaiastatin (2) could not be
converted to (±)-epi-aglaiastatin 18 through treatment with
ammonium formate/formic acid or ammonium formate/heat.
Interestingly, oxazinone (±)-19 was partially converted to
(±)-aglaiastatin (2) and (±)-epi-aglaiastatin 18 in a 2:1 ratio
Table 2. Substrate Scope for Reduction
entry substrate conv, %
ee of reduced product
(yield), %
ee of starting materiala
(yield), %
1 (±)-5b 50 96 (45) >99 (42)
2 (±)-7 20 78 (16) 19 (22)
3 (±)-8 n.r. N/A N/A
4 (±)-9 47 >99 88
5 (±)-10 37 74 (13) 41 (31)
aFor entries 1, 4, and 5, enantioenriched starting material was
converted to the corresponding (−)-rocaglate derivatives via ketol
shift/reduction (vide supra) to measure ee. For entry 2, enantioen-
riched (+)-7 was converted to reduced product (+)-11.
Scheme 1. Synthesis of (+)-Aglaiastatin (2) and
(−)-Aglaroxin C (3) from Hydrate (+)-5b
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favoring (±)-2 when heated in the presence of ammonium
acetate (60 °C, 12 h). Since the formation of aglaiastatin (2)
and epi-aglaiastatin 18 is irreversible, the diastereoselectivity of
these products may be controlled through the Curtin−
Hammett principle24 wherein cyclization occurs faster when
the N-acyliminium reaction center is above the convex face of
the rocaglate scaffold. Figure 5 shows ground state conformers
of N-acyliminium intermediates leading to aglaiastatin (2) and
epi-aglaiastatin 18 calculated in the gas phase using the B3LYP/
6-31G* level of theory.17 These N-acyliminiums feature acetate
counterions that are hydrogen-bonded to both the hydroxyl25
and enamine on the convex face of the rocaglate scaffold.
Intermediate 20a (leading to aglaiastatin) is 2.0 kcal/mol lower
in energy than its corresponding rotamer 20b. This energetic
difference appears to be due to steric repulsion between the 3‴-
methylene of the pyrrolidine and the acetate counterion, and
the N-acyliminium reaction center residing within the concave
face of the cyclopenta[b]benzofuran scaffold. Through invoking
the Hammond postulate, these intermediates provide a
rationale for the observed 10:1 diastereoselectivity using acetate
as counterion. When rotamers 20a and 20b were subjected to a
similar computation with formate as the counterion, the
corresponding formate structures were found to have an energy
difference of 1.0 kcal/mol,19 presumably because of the smaller
counterion size. Furthermore, acetate is more basic than
formate for deprotonation of the enamine as the nitrogen
attacks the N-acyliminium. This explains the greater production
of aglaiastatin (2) vs oxazinone 19 when acetate is the
counterion as compared with formate (cf. Scheme 2). We also
considered that the N-acyliminium cyclization may also occur
through 6π-electrocyclization (Figure 6) in which formation of
aglaiastatin (2) is torquoselective through the aforementioned
steric effects.26 However, this mechanism would require
Scheme 2. Experiments To Probe the Mechanism of N-Acyliminium Cyclizationsa
aConditions: (a) ammonium acetate (10 equiv), THF, 60 °C, 2 h; (b) formic acid (1 equiv), ammonium formate (15 equiv), THF, rt, 6 d (69%
from (±)-5b; no conversion from (±)-2; (c) ammonium formate (10 equiv), THF, 60 °C, 12 h (58% from (±)-5b; no conversion from (±)-2); (d)
ammonium acetate (10 equiv), THF, 60 °C, 12 h.
Figure 4. X-ray structure of oxazinone 19.
Figure 5. Ground state conformers (B3LYP/6-31G*) of N-
acyliminium rotamers 20a and 20b.
Figure 6. Alternative, torquoselective 6π-electrocyclization.
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tautomerization and flattening of the six participating atoms in
order to achieve the orbital alignment necessary for electro-
cyclization.
Biological Evaluation. With the natural products (enan-
tiopure and racemic) and analogues in hand, we tested their
potencies in whole cell assays reporting on several of the
biological activities previously reported for the rocaglate
compound class: inhibition of the HSF1-dependent heat-
shock response, cytotoxicity, and translation inhibition (Table
3).5b Additionally, we synthesized the unnatural enantiomers of
aglaiastatin (2) and aglaroxin C (3) by using the (S,S)
enantiomer of Rh(III) diphenylethylenediamine A in the
kinetic resolution of substrate (±)-5b (cf. Table 1 and Scheme
1), and tested (−)-aglaiastatin (2) and (+)-aglaroxin C (3) in
the aforementioned assays. Figure 5 summarizes the data. The
natural enantiomer, (+)-aglaiastatin (2) was found to be the
most potent with single-digit nanomolar IC50 values obtained
for both heat-shock reporter inhibition and cytotoxicity (entry
1). The racemates of aglaiastatin (2, entry 2) and aglaroxin C
(3, entry 6) were not as potent as their respective natural
enantiomers (entries 1 and 3, respectively), and unnatural
enantiomers (entries 7 and 8, respectively) were significantly
less potent. Interestingly, (+)-2 and (±)-2 (entries 1 and 2,
respectively) were more potent than the positive control
rohinitib (RHT, entry 9), and natural aglaroxin C ((−)-3, entry
3) was found to have similar potencies as RHT. Of note, (−)-2
retains moderate bioactivity suggesting the possibility of an
alternative molecular target(s).27 In general, (±)-epi-aglaiastatin
(18, entry 4) was more potent than (±)-aglaroxin C (3, entry
6), which was more potent than oxazinone (±)-19 (entry 5).
■ CONCLUSION
In summary, we have accomplished a highly enantio- and
diastereoselective kinetic resolution of aglain ketones using
Rh(III)-mediated transfer hydrogenation. This process allows
rapid access to bioactive rocaglate natural products in a
biomimetic fashion. From the substrate scope, it is also evident
that this process can be used to access a variety of enantiopure
aglain and rocaglate analogues. We further demonstrated the
utility of the methodology by enantioselective syntheses of
(+)-aglaiastatin (2) and (−)-aglaroxin C (3). Finally, we tested
both enantiomers of aglaiastatin (2) and aglaroxin C (3) for
several of the most prominent bioactivities reported for this
compound class and found that the natural enantiomers were
most potent. Moreover, we observed a concordance in potency
for all derivatives across the three bioassays, suggesting there
may be a single, conserved molecular target responsible for
their activity. Further work toward the synthesis and biological
evaluation of aglaiastatin and rocaglate analogs is currently in
progress and will be reported in due course.
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Schmidt, H.; Giaisia, M.; Köhler, R.; Müller, W. W.; Proksch, P.;
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